The present invention relates to an improved, commercially viable and industrially advantageous process for the preparation of narwedine, and use thereof in the preparation of galanthamine or salt thereof.

The present invention relates to high drug load pharmaceutical compositions comprising Eslicarbazepine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof. The present invention also relates to a process for preparing high drug load solid oral pharmaceutical compos...

The present invention relates to solid dispersion pharmaceutical. compositions comprising Eslicarbazepine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof. The present invention also relates to a process for preparing such solid oral pharmaceutical compositio...

The present invention relates to a solid oral pharmaceutical composition comprising an effective amount of Esciicarbazepine or its pharmaceutical acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof. The invention also relates to a process for the preparation of a pharmaceutical compos...

The present invention relates to an improved process for the preparation of N-[[2-[[[4- [[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]- 1 -methyl- 1 Hbenzimidazol- 5-yl]carbonyl]-N-2-pyridinyle thyl ester known as dabigatran etexilate or its salts thereof specifically methanesulfonate salt commonly ...

The present invention relates to an improved process for the preparation of pure 10-oxo- 10,ll -dihydro-5H-dibenz[b,f]azepine-5-carboxamideS. Specifically, the present invention relate; to an improved process for the preparation of 10-methoxy-5H-dibenz[b,f]azepine, which is further converted to oxcarbazepine. ...

The present invention provides an improved process for the preparation of polyaminocarboxylates involving use of novel intermediates and is simple, efficient and environment friendly.

The present invention relates to immediate release pharmaceutical compositions comprising Brivaracetam or its pharmaceutically acceptable salts, esters, solvates, derivatives, amides, polymorphs, enantiomers, prodrugs, analogues, active metabolites or mixtures thereof. The present invention also relates to a proc...

The present invention relates to an immediate release solid oral pharmaceutical composition comprising an effective amount of Tizanidine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, stereoisomers or mixtures thereof. The solid oral dosage form comprises one or more methacrylic acid copo...

The present invention relates to pharmaceutical compositions of Lurasidone or its pharmaceutical^ acceptable salts, esters, solvates, polymorphs, stereoisomers or mixtures thereof. The present invention also relates to a process for the preparation of solid oral dosage forms comprising Lurasidone or its pharmaceu...

The present invention relates to a stable, immediate release solid oral pharmaceutical compositions comprising iron chelating agents like Deferasirox and at least one pharmaceutical acceptable excipient wherein the composition is free of glidant. Prior art discloses various technical challenges and suggest restricti...

The present invention relates to high drug load, non-dispersible pharmaceutical compositions comprising iron chelating agents or their pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof wherein, the pharmaceutical composition comprises more than 60% of Deferasirox by ...

The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comprising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at ...

The present invention encompasses improved processes for the preparation of (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)-1-oxoethyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile its salts or hydrates thereof, which is a cyclopropyl-fused pyrrolidine-based dipeptidyl peptidase (DPP) IV inhibitor. ...

The present invention provides an efficient, safe and convenient process for the preparation of Perphenazine of Formula 1. The present invention also provides a process for the purification of Perphenazine by acid-base and activated carbon treatment methods.

The present invention provides an improved process for the preparation of ticagrelor providing it in high yield and high purity. The present invention further involves identification, isolation, characterization and preparation of key process impurities of ticagrelor.

The present invention relates to a solid oral pharmaceutical composition comprising antipsychotic drug like Brexpiprazole or itspharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof and a process for its preparation. The prior art discloses technical challenges such as p...

This invention in general relates to a pharmaceutical composition of Qseltamivir or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof. In particular, the present invention proposes a stable pharmaceutical composition for constitution into solution or suspension c...

The present invention provides an improved, efficient, safe and convenient process for the preparation of labetalol hydrochloride. The present invention also provides a process for the purification of labetalol hydrochloride by using solventlanti-solvent method.

The present invention provides improved processes for the preparation of (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)-1-oxoethyl]-2-azabicyclo[3.1.0] hexane-3-carbonitrile its salts or hydrates thereof. The present invention also provides novel intermediate compounds, which can be used furthe...

The present invention relates immediate release pharmaceutical suspension dosage form of Olmesartan or its pharmaceutical^ acceptable salt, hydrate or polymorph thereof comprising one or more pharmaceutical^ acceptable excipients wherein the pH of the composition is from 4- 8 and viscosity from 700-1100 cps. The inv...

The present invention relates to a stable ready to use and powder for oral suspension dosage forms of Lamotrigine and its pharmaceutically acceptable salts and process of preparing such compositions. The liquid and powder for oral suspension dosage forms of Lamotrigine have been previously known only as extemporaneo...

The present invention discloses a stable pharmaceutical composition for oral administration of fosfomycin comprising a specific ratio of fosfomycin to pH regulating agent, wherein less amount of pH controlling agent is used. The prior art discloses use of higher amount of stabilizers to achieve desired technical att...

This invention in general relates to a stable pharmaceutical composition comprising Ramelteon or its pharmaceutically acceptable salts, polymorphs, enantiomers or mixtures thereof and one or more excipients. In particular, the present invention proposes a stable pharmaceutical composition of Ramelteon free of copoly...

The present invention relates to a novel process for the preparation of safinamide or acid addition salt thereof. The present invention also relates to the process for the preparation of compound of Formula 17A, an intermediate of safinamide. Further, the present invention also relates to a process for the preparati...

The present invention relates to an improved process for the preparation of vortioxetine or salts thereof. The present invention also relates to the process for the preparation of amino intermediate of Formula 4 and its conversion to vortioxetine free base.

The  present  invention  discloses  an  improved  process  for the  preparation  of veratraldehyde which simple and cost-effective. CD

The present invention provides an improved and commercial viable process for the preparation of pure Hydrochlorothiazide of formula I. This processes industrially feasible and cost effective for the preparation of pure Hydrochlorothiazide of formula I.

The present invention relates to an improved, economical and industrially viable process for the preparation of valacyclovir hydrochloride, preferably, valacyclovir hydrochloride in monohydrate form.

The present invention discloses a pharmaceutical composition comprising combination of tadalafil and finasteride used in the treatment of the patients with average severity of LUTS associated with BPH. The prior art discloses use of surfactants and solubilizers to achieve desired technical attributes due to low solu...

The present invention relates to novel orally administered pharmaceutical compositions of Coenzyme QIO and P-Hydroxy (3-methylbutyric acid (HMB). It also relates to the processes for the preparation of said compositions. There is an unmet need of pharmaceutical compositions of Coenzyme QIO and HMB. The present inven...

The present invention provides an improved and industrially feasible and cost effective process for the preparation of Betrixaban of Formula VIII and Betrixaban maleate having Formula IX.

The present invention relates to orally administered liquid pharmaceutical compositions of eslicarbazepine. The liquid compositions are in the form of ready to use suspension and suspension powder for reconstitution. It also relates to the processes for the preparation of said liquid compositions. The present invent...

The present invention provides process for the preparation of brivaracetam. The present invention also provides process for the preparation of intermediate compounds and their use in the preparation of brivaracetam.

The present invention provides an improved and commercial viable process for the preparation of Pirfenidone of formula I. This process is industrially feasible and cost effective process for the preparation of Pirfenidone.

The present invention relates to an improved process for the preparation of 5-chloro-N-({(5S)- 2-oxo-3-[4-(3-5 oxo-4-morpholinyl)phenyl]-l,3-oxazolidin-5yl} methyl)-2-thiophene carboxamide (Rivaroxaban) and intermediates thereof. Also disclosed herein is an improved process for the preparation of rivaroxaban via ...

The present invention relates to an improved process for the preparation of ezogabine which is simple, environment friendly and industrially feasible. The invention further relates to a novel process for the preparation of stable mixture of crystalline modifications of ezogabine.

The present invention relates to a high drug load- pharmaceutical composition comprising an effective amount of Verapamil or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof in combination with suitable excipients. The invention also relates to a process for pre...

The present invention relates to high drug load, controlled release pharmaceutical composition comprising Valproic acid or its pharmaceutically acceptable derivatives, esters, amides, salts, solvates, polymorphs, enantiomers or mixtures thereof wherein, the granules used for the composition do not exhibit stickin...

The present invention relates to a solid oral pharmaceutical dosage form suitable for making a suspension comprising acid labile benzimidazole compounds and process for preparing the same. The prior art discloses various technical challenges associated with the granules for reconstitution into suspension like agglom...

The present invention relates to a pharmaceutical composition in the form of ready to use suspension and suspension powder for reconstitution of valsartan suitable for oral administration. It also relates to a process for the preparation of said compositions. The compositions are convenient for administration by ped...

The present invention provides an improved process for the preparation of Telmisartan its salts and hydrates thereof with high yield, high degree of purity with fewer impurities. Specifically, the invention provides sodium salt of telmisartan sodium, its hydrate and process for preparation thereof. The invention ...

The present invention relates to a stable pharmaceutical composition of tetrofosmin or pharmaceutically acceptable salts thereof. It also relates to a lyophilized non-radioactive kit which upon reconstitution with 99mTc -pertechnetate solution gives a stable 99mTc-tetrofosmin radiopharmaceutical composition. It also...

The present invention relates to an improved process for the preparation of Vildagliptin or salts thereof. The present invention also relates to the process for the preparation of Vildagliptin by coupling of 1-chloroacetyl-2-cyanopyrrolidine of Formula 4 and 3-aminoadamantan-1-01 of Formula 5 in the presence of c...

The invention relates to a commercially viable, cost effective and energy efficient process for the preparation of 2-(l#-Imidazol-4-yl)ethanamine or pharmaceutically acceptable salts thereof in high purity and yield via application of continuous flow technology.

The present invention provides process for the preparation of brivaracetam. The present invention also provides process for the preparation of intermediate compounds and their use in the preparation of brivaracetam.

The present invention relates to a stable modified release oral pharmaceutical multiparticulate composition comprising rabeprazole or its salts thereof. The oral pharmaceutical composition multiparticulates of this invention comprise of a tablet, capsule or a sachet. The commercial multiparticulate based formulation...

This invention in general relates to a pharmaceutical composition comprising Tolvaptan or its pharmaceutically acceptable salts, polymorphs, enantiomers or mixtures thereof and one or more pharmaceutically acceptable excipients. The prior art discloses various technical challenges associated with dissolution of Tolv...

The present invention provides a simple, reproducible and efficient process for the preparation of polymorph of l-(4-fluorobenzyI)-3-(4-isobutoxybenzyl)-l-(lmethylpiperidin- 4-yl)urea tartrate.

The present invention relates to a stable pharmaceutical composition comprising multiparticulate systems of solifenacin or its salts thereof, formulated into a rapidly disintegrating tablet dosage form or into a unit dosage form which can be dispensed in a sachet The prior art discloses restrictive formulation techn...

The present invention relates to a process for the preparation of 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy} quinolin-2(1H)-one (brexpiprazole) from 7-(4-chlorobutoxy)quinolin-2(1H)-one and 1-(benzo[b]thiophen-4-yl)piperazine. The intermediate 7-(4-chlorobutoxy)quinolin-2(1H)-one is prepared from 7-hydroxy...

The present invention relates to gastro-retentive multiparticulate pharmaceutical composition comprising pregabalin. It also relates to a process for the preparation of said composition. The only commercially available extended release dosage form of pregabalin is an extended release tablet. There is an unmet need o...

The present invention relates to an extended release multiparticulate pharmaceutical composition comprising one or more active pharmaceutical ingredient selected from oxcarbazepine or metformin and their salts thereof, formulated into a unit dosage form. The prior art discloses restrictive formulation technique and ...

The present invention relates to a pharmaceutical composition comprising valacyclovir or its pharmaceutically acceptable salts thereof. Particularly, the oral pharmaceutical composition of this invention comprise of a powder for oral suspension or sprinkles encapsulated in capsule or a sachet. The formulation disclo...

The present invention relates to a process for the preparation of ivacaftor. The present invention also relates to the process for the preparation of intermediates of ivacaftor, which are further used for the preparation of ivacaftor.

Disclosed herein are the transdermal drug delivery system of solifenacin or its pharmaceutically acceptable salts, alone or in combination with at least one other drug selected from antiadrenergic, adrenergic, acetylcholinesterase inhibitor(s). The present invention also relates to a process for preparing transderma...

Disclosed herein are the sublingual pharmaceutical compositions comprising remdesivir or its pharmaceutically acceptable salts or solvates thereof. The present invention also relates to a process for preparing sublingual pharmaceutical compositions comprising remdesivir or its pharmaceutically acceptable salts or so...

This invention relates to an improved process for the preparation of Remdesivir and intermediates thereof. Specifically, the present invention discloses a process for the preparation of Remdesivir substantially free of nitrosamine impurities. Further, the improved aspect of the present invention is to provide a proc...

The present invention discloses an extended release oral liquid pharmaceutical composition comprising eslicarbazepine or its pharmaceutically acceptable esters, 5 salts, solvates, polymorphs, enantiomers or mixtures thereof in a pharmaceutically acceptable carrier. The extended release liquid compositions are in the...

This invention relates to a process for the preparation of substituted tetrazole derivative (s) to minimize genotoxic impurities. Specifically, the present invention discloses a process for the preparation of angiotensin-II-receptor blockers essentially free of genotoxic impurities.

The present invention provides a process for preparation of gonadotropin releasing hormone antagonist, elagolix and its intermediates. The invention also provides elagolix intermediates in isolated solid form. The invention further relates to amorphous elagolix sodium with low residual solvent content, essentially f...

The invention relates to process for the preparation of regadenoson. The invention further relates to the use of novel intermediates for the preparation of regadenoson, wherein the process is simple, efficient and economical. ...

The present invention provides an industrially feasible and improved process for the preparation of Remdesivir of Formula XI and intermediates thereof. Further, the present invention also provides novel compound of Formula V and process for its preparation. The present invention provides compound of Formula V having...

The present invention relates to the process for reducing the particle size of Azilsartan or its esters or salts thereof using cryogenic milling process. The conventional milling processes has disadvantage like thermal and chemical decomposition from the high heat generated during the processes. Conversely, the pres...

The present invention relates to stable pharmaceutical compositions of sulfur colloid, which advantageously provide a high radiochemical purity to99mTc-pertechnetate without causing the gel formation. The compositions include pre-lyophilized and lyophilized compositions of sulfur colloid. It also relates to a non-ra...

The present invention relates to the lipid pharmaceutical compositions comprising remdesivir or its pharmaceutically acceptable salts or solvate thereof. The present invention also relates to a process for preparing lipid compositions comprising remdesivir or its pharmaceutically acceptable salts or solvate thereof....

The present invention relates to a stable pharmaceutical composition comprising a combination of chlordiazepoxide hydrochloride and clidinium bromide and one or more pharmaceutically acceptable excipients, wherein the composition is in the form of solid oral dosage forms like capsule and sachet. The technical chal...

The present invention relates to a pharmaceutical composition comprising a hydroxychloroquine or their pharmaceutically acceptable salts thereof, wherein the composition is in the form of a powder for oral suspension or sprinkles encapsulated in capsule or a sachet. The prior art discloses restrictive formulation ...

The present invention relates to the transmucosal dosage forms like sublingual pharmaceutical compositions comprising antiviral molecules like favipiravir, remdesivir, baloxavir marboxil, molnupiravir, besifovir, raltegravir, GS-441524, ravidasvir, and other antiviral drugs. The present invention also relates to met...

The present invention provides an improved process for the preparation of Oxcarbazepine of formula [I]. Further, the present invention provides simple, economical and environment friendly process for preparing Oxcarbazepine in high yield and purity. Specifically, the present invention relates to process for the prep...

The present invention provides an improved and industrially feasible and cost effective process for the preparation of Empagliflozin having Formula X.

The present invention relates to an improved process for the preparation of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-5-oxo-4-morpholinyl)phenyl]-l,3-oxazolidin-5yl}methyl)-2-thiophene carboxamide (Rivaroxaban) with high yield, high degree of purity with fewer impurities, which is economically viable on commercial scale. Spec...

The present invention provides a process for preparation of hydronopol, a key intermediate of 5 pinaverium bromide. Specifically, the present invention relates to a single step process for the preparation of hydronopol from nopol with high chiral purity, yield and without use of toxic reagents. The present invent...

The present invention relates to immediate release suspension dosage form of solifenacin and its pharmaceutical^ acceptable salts. The present invention also relates to manufacture of liquid and powder for oral suspension dosage forms of solifenacin with desired technical attributes. The prior art discloses restrict...

This invention relates to a process for the preparation of bumetanide providing bumetanide essentially free of genotoxic impurities preferably nitrosamine impurities.

The present invention relates to a process for the preparation of angiotensin receptor blockers or its pharmaceutically acceptable salts thereof containing less than 10 ppm of the azido impurities. More particularly, the present invention relates to process for the preparation of Losartan, Losartan potassium of Form...

ABSTRACT The present invention relates to a pharmaceutical immediate release oral liquid formulation of tramadol. In particular, the present invention provides a pharmaceutical oral solution of tramadol. It also relates to the process for the preparation of said liquid formulation. It further relates to the use of ...

The present invention provides an improved process for the preparation of Molnupiravir of Formula I. Further, the present invention provides simple, economical and environment friendly process for preparing Molnupiravir, in high yield and purity. The present invention provides an improved process for the preparation...

The present invention relates to orally administered extended release pharmaceutical compositions of gabapentin enacarbil. It also relates to the processes for the preparation of said extended release compositions. It further relates to the use of the extended release pharmaceutical compositions for the treatment of...

The present invention relates to a process for the preparation of 2-butyl-4-chloro-5-formyl imidazole of Formula I. Further, the present invention provides simple, economical, industrially efficient and green process for the preparation of 2-butyl-4-chloro-5-formyl imidazole. The present invention provides an improv...

The present invention relates to a process for the preparation of Donepezil hydrochloride. Further, the present invention provides simple, economical and environment friendly process for the preparation of Donepezil hydrochloride monohydrate of Formula I, in high yield...

The present invention relates to solid oral pharmaceutical compositions comprising varenicline or its pharmaceutically acceptable salts thereof. The present invention also relates to a process for preparing solid oral pharmaceutical compositions comprising varenicline or its pharmaceutically acceptable salts th...

The present invention relates to a process for the preparation of Tafamidis and its salts thereof. Specifically, the present invention relates to process for preparation of Tafamidis and its salts involving coupling of 4-amino-3-hydroxybenzoic acid or its alkyl ester with 3,5-dichlorobenzoic acid. More particularly,...

ABSTRACT The present invention relates to a process for the preparation of acetyl iminostilbene and/or iminostilbene (5H-dibenzo [b,f] azepine). Further, the present invention discloses a commercially viable, cost effective and energy efficient process for the preparation of carbamazepine, oxcarbazepine or impramin...